Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus Anlotinib after adjuvant third-generation EGFR-TKI progression in EGFR-mutant NSCLC
ChiCTR2500114326Phase 4Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival. Started Dec 2025; status: recruiting.
02
Drugs
almonertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114326.